Penghua CSI Chinese Medicine ETF

Madrigal's Rezdiffra Strong Sales, ZSP1601 Shows Potential in Anti-Fibrotic Therapy

ZZPZH released FY2025 earnings on April 29 After-Market (BJT), actual revenue CNY 9.001 B (forecast CNY 9.878 B), actual EPS CNY 3.58 (forecast CNY 4.2437)

DRTG released FY2026 Q1 earnings on April 29 After-Market BJT, actual revenue CNY 1.515 B, actual EPS CNY 0.55

Yunnan Baiyao released FY2026 Q1 earnings on April 29 During-Market (BJT), actual revenue CNY 11.6 B (forecast CNY 11.04 B), actual EPS CNY 1.14 (forecast CNY 0.9224)

TRT released FY2026 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 4.664 B (forecast CNY 5.091 B), actual EPS CNY 0.344 (forecast CNY 0.35)

ZZPZH released FY2026 Q1 earnings on April 29 Pre-Market (BJT), actual revenue CNY 2.741 B (forecast CNY 3.114 B), actual EPS CNY 1.23 (forecast CNY 1.78)

JI LIN AO DONG released FY2026 Q1 earnings on April 29 After-Market (BJT), actual revenue CNY 514.09 M, actual EPS CNY 0.7387

ZZPZH released FY2025 Q4 earnings on April 29 After-Market (BJT), actual revenue CNY 1.559 B (forecast CNY 2.194 B), actual EPS CNY 0.0486 (forecast CNY 1.11)

JD Health and China Resources Sanjiu Collaborate to Extend TCM Services to Grassroots

ZHONGSHENGYAOYE released FY2025 Q4 earnings on April 28 Pre-Market (BJT), actual revenue CNY 633.98 M, actual EPS CNY 0.03

ZHONGSHENGYAOYE released FY2025 earnings on April 28 Pre-Market (BJT), actual revenue CNY 2.523 B (forecast CNY 3.121 B), actual EPS CNY 0.33 (forecast CNY 0.43)

ZHONGSHENGYAOYE released FY2026 Q1 earnings on April 28 After-Market BJT, actual revenue CNY 624.24 M, actual EPS CNY 0.12

Yiling Pharmaceutical released FY2025 earnings on April 27 After-Market (BJT), actual revenue CNY 7.831 B (forecast CNY 10.09 B), actual EPS CNY 0.77 (forecast CNY 0.72)

GYBYS released FY2026 Q1 earnings on April 27 During-Market (BJT), actual revenue CNY 23.28 B, actual EPS CNY 1.097

Yiling Pharmaceutical released FY2026 Q1 earnings on April 27 Pre-Market (BJT), actual revenue CNY 2.44 B, actual EPS CNY 0.2447

Yiling Pharmaceutical released FY2025 Q4 earnings on April 27 After-Market (BJT), actual revenue CNY 1.963 B, actual EPS CNY 0.1712

CR Pharm 华润三九 Q1 2026 Revenue 8.13B yuan, Net Profit 1.209B yuan

DEEJ released FY2026 Q1 earnings on April 24 Pre-Market (BJT), actual revenue CNY 1.814 B (forecast CNY 1.978 B), actual EPS CNY 0.708 (forecast CNY 0.7416)

CR Sanjiu released FY2026 Q1 earnings on April 24 During-Market (BJT), actual revenue CNY 8.13 B (forecast CNY 6.79 B), actual EPS CNY 0.65 (forecast CNY 0.6298)

JI LIN AO DONG to Release FY2026 Q1 Earnings on April 30 After-Market (BJT)

399933

165519

159647

161726

The Penghua CSI Chinese Medicine ETF rose by more than 1.8%, influenced by the opinions on the pricing mechanism for pharmaceuticals released by the General Office of the State Council. The opinion aims to regulate the prices of raw and auxiliary materials for medicines and promote the development of high-quality and high-priced Chinese medicinal materials. Institutional analysis suggests that Chinese medicine companies have low valuations and high dividend rates, and will benefit from policy support and market recovery in the future. The CSI Chinese Medicine Index rose by 2.04%, with many Chinese medicine stocks performing strongly. Overall, the state supports the development of traditional Chinese medicine, and the industry is expected to achieve high-quality growth

腾讯新闻 - 财经

800 Health Care

CITIC-Prudential CSI 800 Pharmaceuticals and Biotechnology Index Fund(LOF)-A

China Merchants CNI BIOMEDICINE Index Fund-A

CONBA

Zhongheng Group

BUCHANG PHARMA

ZHONGSHENGYAOYE

YABAO PHARM.CORP

Yunnan Baiyao

ZZPZH

DEEJ

CR Sanjiu

JI LIN AO DONG

GYBYS

BAIYUNSHAN PH

YILING PHARMACEUTICAL

DRTG

TONG REN TANG

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

603858

Penghua CSI Chinese Medicine ETF net subscribed 36.5 million units, and the State Administration for Market Regulation approved three national standards in the field of acupuncture, which will be implemented starting October 1. Zhongtai Securities analysis pointed out that the reform of medical insurance payment promotes the construction of the clinical value evaluation system for traditional Chinese medicine, and traditional Chinese medicine products with RCT evidence chains are more likely to gain access to medical insurance. The performance of the CSI Traditional Chinese Medicine Index constituent stocks was poor, with BUCHANG PHARMA leading the decline at 3.17%. Penghua CSI Chinese Medicine ETF closely tracks the CSI Traditional Chinese Medicine Index, reflecting the overall performance of listed companies in the traditional Chinese medicine concept

Capital allocation, Penghua CSI Chinese Medicine ETF net subscription of 36.5 million units, policies continuously improving to support the development of traditional Chinese medicine

The Ministry of Industry and Information Technology and eight other departments issued the "Implementation Plan for the High-Quality Development of the Traditional Chinese Medicine Industry," aimed at increasing the cultivation of listed traditional Chinese medicine enterprises. The plan emphasizes creating a fair competitive market environment, stimulating the development potential of enterprises, and promoting the collaborative development of the traditional Chinese medicine industry. At the same time, it supports leading enterprises in establishing industrial development funds and encourages financial institutions to provide financial services for traditional Chinese medicine enterprises

36Kr

Eight departments: Increase efforts to cultivate the listing of traditional Chinese medicine industrial enterprises

Penghua CSI Chinese Medicine ETF(159647.SZ)

Penghua CSI Chinese Medicine ETF rose over 1.8%, as policies strengthen guidance on medicinal material prices, promoting a quality and price-oriented approach

Capital allocation, Penghua CSI Chinese Medicine ETF net subscription of 36.5 million units, policies continuously improving to support the development of traditional Chinese medicine

Eight departments: Increase efforts to cultivate the listing of traditional Chinese medicine industrial enterprises